Changes in glitazone use among office-based physicians in the U.S., 2003-2009

Diabetes Care

Volumn 33, Issue 4, 2010, Pages 823-825

  Cohen, Andrew ^a   Rabbani, Atonu ^b,c   Shah, Nilay ^d   Alexander, G Caleb ^b,c,e,f  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d Mayo Clinic   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; DIABETES MELLITUS; DRUG CHOICE; DRUG MARKETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; MASS MEDIUM; OBSERVATION; TIME SERIES ANALYSIS; UNITED STATES;

DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; HUMANS; HYPOGLYCEMIC AGENTS; PHYSICIAN'S PRACTICE PATTERNS; THIAZOLIDINEDIONES; UNITED STATES;

EID: 77953073836     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1834     Document Type: Article

References (13)

1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
2. Wooltorton E. Rosiglitazone (avandia) and pioglitazone (actos) and heart failure. CMAJ 2002;166:219 (Pubitemid 34298034)
3. Nissen SE, Wolski K. Effect of rosiglita-zone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471
4. Federal Drug Administration, Center for Drug Evaluation and Research. Label and approval history [Internet]. Available at http://www.accessdata.fda. gov/Scripts/cder/drugsatfda/index.cfm?fuseaction=search.label- ApprovalHistory#apphist. Accessed 1 July 2009
5. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing medications for policy and research initiatives examining off-label prescribing. Pharmacotherapy 2008;28:1443-1452
6. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment for type 2 diabetes mellitus, 1994-2007. Arch Intern Med 2008;168:2088-2094
7. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-351
8. McDowall D. Interrupted Time Series Analysis. Vol 21. Beverly Hills, CA, and London, Sage, 1980
9. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165:171-177
10. Berwick DM. Disseminating innovations in health care. JAMA 2003;289:1969-1975
11. Dormandy J, Van Troostenburg de Bruyn A, Bhattacharya M. Overall safety of pioglitazone in high-risk patients with type 2 diabetes. Drug Saf 2009;32:187-202
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188
13. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007;357:67-69